Prospective Cohort Study Investigating Vaccine-Induced Immune Responses Against Respiratory Viral Infections in Immunocompromised Patients With or Without Hematological Conditions

What this Trial Is About

Researchers are studying the immune responses to vaccines against respiratory viruses in immunocompromised patients, including those with hematological or oncological conditions. These patients often have weakened immune systems due to disease or treatment, making them more vulnerable to severe respiratory infections from viruses like influenza, RSV, and coronaviruses. The study aims to better understand how vaccine-induced immunity, especially T cell responses, functions in these patients, as current data mostly focuses on antibody responses which may be less effective in this group. This observational study will analyze early and late booster vaccinations in immunocompromised patients who are vaccinated as part of routine care. It will focus on measuring virus-specific T cell responses and humoral immune responses over time. The research will gather blood samples and other data to assess the cellular and antibody responses to vaccination, helping to fill knowledge gaps about long-term protection in this vulnerable population. Participants will be monitored for up to 12 months after vaccination to evaluate humoral and cellular immune responses, including seroconversion. The study will collect and analyze samples at various points to measure these immune markers. The University of Cologne leads this research, which seeks to improve understanding of vaccine effectiveness and guide better preventive strategies for immunocompromised patients facing respiratory viral infections.

Vaccine-induced Immunity in Immunocompromised Patients